The AstraZeneca share price is climbing. Is growth really here again?

The AstraZeneca share price has been volatile in recent years, though we’ve seen a strong run since March. Will I buy at today’s valuation?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After Pascal Soriot took the helm during crisis time at AstraZeneca (LSE: AZN), it was always going to take a while to turn things round. Maybe about five years, I thought, back in 2012. Still, the pharmaceuticals giant recorded a hefty 2020 profit rise after several years of falls. And the AstraZeneca share price had already been gaining in anticipation of a return to long-term growth.

Since early 2019, the shares have been climbing. And over a five-year period, they’ve more than doubled in price. The last 12 months have been a bit rocky, with the company getting into troubles with the European Union over shipments of Covid-19 vaccine.

But, since early March, we’re looking at a steady rise again. A first-quarter earnings call at the end of April gave AstraZeneca shares another boost, and they’ve continued upwards since. My Motley Fool colleague Pam Narang has picked up on some of the main points of AstraZeneca’s key drug developments, so I won’t repeat them here.

But, to summarise, AstraZeneca is making impressive progress in its key lines of oncology and diabetes research. So I really don’t think we should see the AstraZeneca share price as a Covid-19 play. I do fear, however, that’s how a lot of investors see it right now.

AstraZeneca share price valuation

Will I buy? That depends on whether the company really has got its pipeline primed to produce regular successes in the coming years. And if I think we can expect a period of steady earnings growth. I can’t tell from the Q1 figures, which were skewed by the disposal of AstraZeneca’s 26.7% share of Viela Bio. That raised a profit of $776m. First-half results, due in July, will be fuller and will hopefully give me a better insight.

In the meantime, I’m thinking about the AstraZeneca share price valuation. They ended 2020 on a P/E of around 40. And this year’s share price gains push that trailing multiple as high as 47. That’s the kind of level I’d expect for a smaller growth stock, and it does seem to assume there’ll be some stellar growth from AstraZeneca in the next few years.

And AstraZeneca shares have been volatile, and do seem to be cyclical. Even with no obvious change in the company’s long-term outlook, investors can swing from not touching it with a bargepole, to pumping it up like the next great growth stock.

Waiting for steadier times

As I suggested, I really do think Covid-19 lies behind a lot of the current AstraZeneca share price bullishness. But I don’t expect it to figure greatly in the company’s long-term future. Covid has quickly become one of the world’s best-researched ailments. While the worldwide effort has been nothing short of remarkable, it does mean there’s huge competition out there for these vaccines.

Right now, I’m not going to buy. Today’s valuation, and the Covid-19 effect, make me want to wait until things are more settled. And when the dividend starts rising again, that’s when I’ll be truly convinced that sustainable earnings growth is back.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British bank notes and coins
Investing Articles

Should I buy M&G shares for the 9.8% dividend yield?

With the M&G dividend yield close to double digits, this existing shareholder explains why he'd happily buy more of the…

Read more »

British Isles on nautical map
Investing Articles

This cheap UK stock could rise 30%, the City says

Analysts covering Serco Group shares reckon they could rise by over a quarter. But is this UK stock a good…

Read more »

2024 year number handwritten on a sandy beach at sunrise
Investing Articles

Here’s how I’d aim for a million by investing £45 a day

Christopher Ruane thinks putting £45 a day into blue-chip shares could help him aim for a million. Here are some…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

I’d buy FTSE 100 shares in December before the next stock market rally!

Christopher Ruane explains why he would happily snap up cheap FTSE 100 shares between now and the end of the…

Read more »

Businesswoman calculating finances in an office
Investing Articles

6% yield and 8% annual revenue growth! A passive income opportunity

Why not have the best of both worlds? Our writer explores a passive income opportunity with a 6% yield, bolstered…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’ve been loading up on this FTSE 250 share in November!

Christopher Ruane explains why he's been adding even more shares in this well-known FTSE 250 name to his portfolio this…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

Down 30%, these cheap shares are on sale!

Cheap shares don’t mean anything to our analyst unless there’s real value in what he’s buying. Let’s see his Foolish…

Read more »

Photo of a man going through financial problems
Investing Articles

I can’t believe how far these FTSE 100 shares have fallen!

While the FTSE 100 is up 0.7% over six months, these five Footsie flops have collapsed 26% to 40%. But…

Read more »